VJHemOnc is committed to improving our service to you

ASH 2019 | Beat AML Master Trial: novel precision medicine approach in AML

VJHemOnc is committed to improving our service to you

Amy Burd

Amy Burd, PhD, Leukemia and Lymphoma Society, White Plains, NY, discusses the results of the Beat AML master trial (NCT03013998). This study was designed to assess the possibility of using genetic profiling to assign older patients with previously untreated acute myeloid leukemia (AML) to molecularly defined, subtype-specific therapies. Data from this study support the use of precision medicine, patients with AML who elected for treatment assignment based upon cytogenetic and molecular alterations had significantly improved overall survival when compared with those who elected for standard of care treatment. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter